Novo Nordisk vs. Eli Lilly: Inside the GLP-1 False Advertising Lawsuit
The rivalry between the world’s two dominant weight-loss and diabetes drug makers has escalated into a full-blown federal lawsuit. On July 21, 2026, Novo Nordisk Inc. filed suit against Eli Lilly and Company and its subsidiary Lilly USA, LLC in the U.S. District Court for the District of New Jersey, accusing Lilly of running a coordinated, nationwide false-advertising campaign for its blockbuster GLP-1 drugs Zepbound and Mounjaro. The 53-page complaint pdf, filed by the law firm Debevoise & Plimpton, asks the court for injunctive relief, corrective advertising, and monetary damages under the Lanham Act and New Jersey unfair competition law.
At its core, this is a dispute about dosing. Novo Nordisk alleges that Lilly’s ads compare the highest available doses of its own drugs to older, lower doses of Novo’s Wegovy and Ozempic — doses that are no longer the most effective options on the market — while downplaying or burying the existence of Novo’s newer, more potent formulations.
Why Novo Nordisk Says It Had to Sue
According to both the complaint and Novo’s public statement announcing the case, the company sent Lilly a formal cease-and-desist letter on April 22, 2026, objecting to Lilly’s continued use of outdated trial data in its Zepbound television campaign. Novo says Lilly never substantively responded, missing a self-imposed May 6 deadline, and only made minor cosmetic edits to its ads rather than pulling or correcting them. That refusal, Novo says, forced the lawsuit.
Novo Nordisk’s general counsel, John F. Kuckelman, framed the issue as one of corporate responsibility rather than just competitive rivalry, arguing that companies have an obligation to keep public health claims current and that thin, easy-to-miss disclaimers don’t fix a misleading message built into a major national ad campaign. Novo has also warned that if Lilly does not voluntarily withdraw the ads, it intends to seek a preliminary injunction to block them immediately while the broader case proceeds.
The Zepbound vs. Wegovy Allegations
The centerpiece of Novo’s complaint is a national Zepbound television and digital campaign that shows a side-by-side comparison: Zepbound patients losing an average of 50 pounds against 33 pounds for Wegovy patients. That figure comes from SURMOUNT-5, a Lilly-sponsored trial published in May 2025 that tested Zepbound’s two highest doses (10 mg and 15 mg) against Wegovy’s two lowest maintenance doses at the time (1.7 mg and 2.4 mg).
Novo’s problem with that comparison is timing. In March 2026, the FDA approved a new, higher 7.2 mg dose of Wegovy, based on Novo’s STEP UP clinical trial. That 72-week, double-blind, placebo-controlled study of more than 1,400 adults with obesity found that patients on the 7.2 mg dose lost an average of about 18.8% of their body weight — roughly 47 pounds — compared to just 3.9% for those on a placebo. Novo argues that once the 7.2 mg dose became available, the SURMOUNT-5 comparison stopped reflecting the real choice patients face and became misleading by omission.
The complaint goes further, pointing to Lilly’s own double-blind SURMOUNT-1 trial from 2022, which found that Zepbound’s 15 mg dose produced average weight loss of 20.9%, or about 48 pounds. Novo argues that lining up STEP UP’s results for high-dose Wegovy against SURMOUNT-1’s results for high-dose Zepbound shows the two drugs are, in the company’s words, clinically consistent — not the dramatic gap suggested by the 50-pounds-versus-33-pounds ad. Because no company has ever run a true head-to-head trial pitting the highest doses of both drugs against each other directly, Novo contends Lilly has no scientific basis for claiming outright superiority.
Novo’s complaint also faults Lilly for relying on an open-label design in SURMOUNT-5, meaning patients and researchers both knew which drug each participant was taking — a design the complaint says is inherently less reliable than the double-blind, placebo-controlled STEP UP and SURMOUNT-1 trials, since knowledge of the assigned treatment can influence self-reported outcomes like appetite and adherence. Notably, Lilly’s own disclaimer on the Zepbound ad concedes the underlying study data was collected in a less-rigorous design with less-certain findings — language Novo says undercuts Lilly’s simultaneous claim that the comparison proves clear product superiority.
The Footnote Problem
Novo takes particular issue with how Lilly disclosed the existence of high-dose Wegovy after receiving the cease-and-desist letter. Rather than pulling the ad, Lilly added small-print language noting that the higher Wegovy dose wasn’t evaluated in the underlying study but has since been approved. According to the complaint, that disclosure appears in fine print at the bottom of a busy screen, visually subordinate to the bold, prominently displayed 50-pounds-versus-33-pounds graphic and reinforced by voiceover narration. Novo argues the disclaimer never actually tells consumers that the newer Wegovy dose produces results close to Zepbound’s — meaning even an attentive viewer would still walk away believing Zepbound is dramatically more effective.
The complaint also flags a TikTok and Facebook version of the ad campaign, launched around June 2026, which describes the SURMOUNT-5 comparison as a head-to-head study and follows the weight-loss figures with a tagline suggesting the numbers speak for themselves. Novo argues that framing falsely signals the comparison is complete and objective when it omits the newer, more comparable Wegovy dosing data.
Novo says the stakes are significant: the revised Zepbound TV commercial has drawn more than 700 million impressions since it began airing around April 27, 2026, a scale Novo cites as evidence of the competitive harm it’s suffering.
The Mounjaro vs. Ozempic Allegations
Novo brings a parallel claim over Lilly’s advertising for Mounjaro, its tirzepatide drug for type 2 diabetes. Lilly’s national commercial and website advertising highlight a study showing Mounjaro’s 15 mg dose reducing A1c (a standard measure of blood sugar control) by 2.3%, compared to 1.9% for Ozempic’s 1 mg dose. That data comes from SURPASS-2, a Lilly-sponsored trial published in 2021 that compared three Mounjaro doses (5 mg, 10 mg, and 15 mg) against a single, now-outdated Ozempic dose.
The complaint notes that the FDA approved a higher, 2 mg maintenance dose of Ozempic more than four years ago — a dose SURPASS-2 never tested. According to Novo’s complaint, a separate trial known as SUSTAIN FORTE found that the 2 mg Ozempic dose achieved an average A1c reduction of 2.1%, a figure much closer to Mounjaro’s advertised results than the 1.9% figure Lilly features. Novo says Lilly’s Mounjaro ads disclose the existence of the 2 mg Ozempic dose only in a brief line noting it wasn’t available at the time of the study — language the complaint calls inadequate because it never explains that the higher dose actually narrows the gap Lilly advertises. Unlike the Zepbound ad, Novo notes, the Mounjaro campaign doesn’t even disclose that SURPASS-2 was an open-label trial with the same reliability limitations as SURMOUNT-5.
A Broader Pattern: The Orforglipron Allegations
Novo’s complaint doesn’t stop at Zepbound and Mounjaro. It also describes what it calls a broader pattern of similar conduct involving Lilly’s oral GLP-1 drug orforglipron, marketed as Foundayo. In September 2025, Lilly issued a press release touting orforglipron as superior to oral semaglutide in a head-to-head trial, citing weight-loss figures suggesting a large relative improvement over Novo’s oral semaglutide products.
According to the complaint, that claim was based on Lilly’s ACHIEVE-3 trial, an open-label diabetes study that compared orforglipron only to the lower-dose Rybelsus tablets approved for diabetes — not to the higher 25 mg oral semaglutide dose that was, at the time, still pending FDA approval for weight loss. Novo alleges Lilly issued the release knowing that its own application for a 25 mg oral semaglutide weight-loss tablet was under FDA review and likely to be approved by the end of 2025. That approval came in December 2025, when the FDA cleared the Wegovy tablet, and Novo says the pivotal trial behind that approval showed greater weight-loss efficacy than the trial behind orforglipron’s highest dose. Novo frames the orforglipron episode as evidence that its complaint about Zepbound and Mounjaro isn’t an isolated dispute but part of a recurring strategy of advertising Lilly’s drugs against outdated or mismatched comparators.
The Market and Financial Stakes
The complaint devotes significant space to establishing just how much is riding on these advertising claims. It cites Novo Nordisk’s obesity-drug sales climbing from about $1.3 billion annually shortly after Wegovy’s 2021 launch to roughly $12.6 billion annually within four years, and describes Novo as holding a leading global share of the GLP-1 diabetes market, powered largely by Ozempic, which generated around $19.4 billion in sales in 2025. It also cites industry projections estimating more than 30 million Americans could be using a GLP-1 medication by 2030, with global demand potentially reaching $190 billion by 2035.
The complaint also stresses that Wegovy and Ozempic carry FDA-approved indications — including reducing cardiovascular risk, and for Wegovy, treating a liver condition called MASH, and for Ozempic, protecting kidney function — that Lilly’s competing drugs do not currently have. Novo argues those additional benefits become far more relevant to patients once the false weight-loss or A1c gap Lilly advertises is corrected, since patients might otherwise dismiss Novo’s drugs as simply less effective across the board.
The Legal Theory
Novo’s complaint brings three counts. The first alleges violations of Section 43(a) of the Lanham Act, the federal statute that prohibits false or misleading advertising likely to deceive consumers and cause competitive injury. The second alleges unfair competition under New Jersey’s state unfair competition statute, and the third alleges unfair competition under New Jersey common law. All three counts rest on the same underlying theory: that Lilly’s ads are false by necessary implication, meaning that even if individual data points in the ads are technically accurate as far as they go, the overall message the ads convey — sweeping, current superiority — is false given the fuller, more recent clinical picture.
Novo is asking the court for both preliminary and permanent injunctions barring Lilly from running the challenged Zepbound and Mounjaro comparisons, or any similar advertising based on the same outdated trials, unless it’s clearly limited to conversations with healthcare professionals rather than consumers. Novo also wants a court-ordered corrective advertising campaign, monetary damages (with the possibility of treble damages under the Lanham Act), disgorgement of Lilly’s related profits, and its attorneys’ fees and costs.
Eli Lilly’s Response
Lilly is not conceding any ground. In a public statement responding to the lawsuit, the company said it stands firmly behind its advertising, arguing that a well-designed, head-to-head clinical trial remains the gold standard for comparing medicines — a reference to SURMOUNT-5, still the only trial that has directly pitted Zepbound and Wegovy against each other in the same study. Lilly said its messaging is grounded in the most direct scientific evidence currently available and said it intends to defend against the lawsuit vigorously.
That defense highlights the central scientific disagreement in the case. Lilly’s position is that indirect comparisons across separate trials — like lining up STEP UP’s results for Wegovy against SURMOUNT-1’s results for Zepbound, as Novo does — are inherently less reliable than a single trial that tested both drugs in the same patient population under the same conditions, even if that trial is now several years old and didn’t test the newest available doses. Novo’s position is the opposite: that continuing to advertise a stale, real head-to-head comparison as current proof of superiority is more misleading than acknowledging the absence of an up-to-date trial altogether.
What Happens Next
Novo Nordisk has said it will move for a preliminary injunction in the coming days if Lilly does not pull the disputed ads voluntarily, which would force an early court ruling on whether Lilly must stop running the campaigns while the underlying case proceeds through discovery and, potentially, trial. Given the scale of the GLP-1 market and the size of both companies’ advertising budgets, the case is likely to draw close attention from pharmaceutical marketers, health-law practitioners, and consumer advocates alike, and it could set an important precedent for how comparative drug advertising is regulated as the science behind these medicines continues to evolve rapidly.
For now, both companies are girding for a legal fight that, whatever its outcome, is unfolding in full public view — in an industry where advertising claims translate directly into prescriptions, market share, and, according to both sides, patients’ health decisions.